ReviewGut2024
Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
Review in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 48 citations in OpenAlex.
- Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.Scientific reports · 2026Trial
- Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers.Journal of hepatology · 2026Review
- [Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease.Diagnostics (Basel, Switzerland) · 2026Review
- MMP8/PPAR-γ regulation of macrophage-mediated inflammatory response in the pathogenesis of acute-on-chronic liver failure.Cell death & disease · 2026Article
- Palliative Healthy Donor Stool Transplantation (pFMT) in Patients with End-Stage Alcohol-Related Cirrhosis and Severe Unstable Decompensations-A Cohort Study.Journal of clinical medicine · 2026Article
- Unique gut microbiota and metabolomic profiling as biomarker of post-transplant recovery in acute-on-chronic liver failure after liver transplantation.Applied microbiology and biotechnology · 2026Article
- Effect of Intraoperative Dexmedetomidine Use on Postoperative Liver Function and Graft Outcomes in Laparoscopic Living Donor Hepatectomy: A Propensity Score-Matched Study.Journal of clinical medicine · 2026Article
- Detection of Liver Dysfunction in Severe Burn Injury with Bedside Measurement of Perfusion.Medicina (Kaunas, Lithuania) · 2026Observational
- A novel nomogram based on inflammatory indexes for predicting short-term prognosis in acute-on-chronic liver failure: a comparison with classical models.European journal of medical research · 2026Article
- Integrated WGCNA of lncRNA-mRNA Networks Identifies Novel Hub Genes and Potential Therapeutic Agents for Liver Cirrhosis via Molecular Docking Validation.International journal of molecular sciences · 2026Article
- Risk factors for pneumonia, hepatic encephalopathy, and acute kidney injury in patients with hepatitis B virus-related acute-on-chronic liver failure.Frontiers in medicine · 2026Article
- Prognostic Biomarkers for Predicting Decompensation in Alcoholic and Nonalcoholic Patients With Compensated Cirrhosis: An Umbrella Review.Biochemistry research international · 2026Review
- Gut microbiota dysbiosis aggravates liver injury in acute-on-chronic liver failure through D-lactate accumulation.Frontiers in microbiology · 2026Article
- Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation.Gastroenterology · 2026Article
- Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators.PloS one · 2026Article
- Radix Rehmanniae Praeparata Extract Enhances Liver Regeneration Through AMPK-Driven Metabolic Reprogramming.Nutrients · 2025Article
- The pathophysiological role of portal hypertension in metabolic dysfunction-associated steatotic liver disease.Hepatology communications · 2025Review
- Diagnosis of Portal Hypertension.Diagnostics (Basel, Switzerland) · 2025Review
- Study on the prediction of prognosis of patients with acute liver failure treated with artificial liver by serum NLR and IL-6 levels.Journal of medical biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF.Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated cirrhosis and ACLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.